Global Cancer Immunotherapy Drug Supply, Demand and Key Producers, 2023-2029
The global Cancer Immunotherapy Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).
This report studies the global Cancer Immunotherapy Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Cancer Immunotherapy Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cancer Immunotherapy Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Cancer Immunotherapy Drug total production and demand, 2018-2029, (K Units)
Global Cancer Immunotherapy Drug total production value, 2018-2029, (USD Million)
Global Cancer Immunotherapy Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Cancer Immunotherapy Drug consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Cancer Immunotherapy Drug domestic production, consumption, key domestic manufacturers and share
Global Cancer Immunotherapy Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Cancer Immunotherapy Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Cancer Immunotherapy Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Cancer Immunotherapy Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Autolus Therapeutics plc, BeiGene, bluebird bio, Inc., Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Gilead Sciences, Inc., Incyte Corporation and Jiangsu Hengrui Medicine, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Cancer Immunotherapy Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Cancer Immunotherapy Drug Market, By Region:
1. How big is the global Cancer Immunotherapy Drug market?
2. What is the demand of the global Cancer Immunotherapy Drug market?
3. What is the year over year growth of the global Cancer Immunotherapy Drug market?
4. What is the production and production value of the global Cancer Immunotherapy Drug market?
5. Who are the key producers in the global Cancer Immunotherapy Drug market?
6. What are the growth factors driving the market demand?
This report studies the global Cancer Immunotherapy Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Cancer Immunotherapy Drug, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cancer Immunotherapy Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Cancer Immunotherapy Drug total production and demand, 2018-2029, (K Units)
Global Cancer Immunotherapy Drug total production value, 2018-2029, (USD Million)
Global Cancer Immunotherapy Drug production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Cancer Immunotherapy Drug consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Cancer Immunotherapy Drug domestic production, consumption, key domestic manufacturers and share
Global Cancer Immunotherapy Drug production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Cancer Immunotherapy Drug production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Cancer Immunotherapy Drug production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Cancer Immunotherapy Drug market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Autolus Therapeutics plc, BeiGene, bluebird bio, Inc., Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Gilead Sciences, Inc., Incyte Corporation and Jiangsu Hengrui Medicine, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Cancer Immunotherapy Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Cancer Immunotherapy Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- PD-1 Inhibitor
- PDL-1 Inhibitor
- T-Cell Stimulant
- CTLA Antibody
- Hospital
- Clinic
- Others
- Autolus Therapeutics plc
- BeiGene
- bluebird bio, Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- AstraZeneca plc
- Gilead Sciences, Inc.
- Incyte Corporation
- Jiangsu Hengrui Medicine
- Juno Pharmaceuticals Pty Ltd.
- Medimmune, LLC
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Roche Holding AG
1. How big is the global Cancer Immunotherapy Drug market?
2. What is the demand of the global Cancer Immunotherapy Drug market?
3. What is the year over year growth of the global Cancer Immunotherapy Drug market?
4. What is the production and production value of the global Cancer Immunotherapy Drug market?
5. Who are the key producers in the global Cancer Immunotherapy Drug market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Cancer Immunotherapy Drug Introduction
1.2 World Cancer Immunotherapy Drug Supply & Forecast
1.2.1 World Cancer Immunotherapy Drug Production Value (2018 & 2022 & 2029)
1.2.2 World Cancer Immunotherapy Drug Production (2018-2029)
1.2.3 World Cancer Immunotherapy Drug Pricing Trends (2018-2029)
1.3 World Cancer Immunotherapy Drug Production by Region (Based on Production Site)
1.3.1 World Cancer Immunotherapy Drug Production Value by Region (2018-2029)
1.3.2 World Cancer Immunotherapy Drug Production by Region (2018-2029)
1.3.3 World Cancer Immunotherapy Drug Average Price by Region (2018-2029)
1.3.4 North America Cancer Immunotherapy Drug Production (2018-2029)
1.3.5 Europe Cancer Immunotherapy Drug Production (2018-2029)
1.3.6 China Cancer Immunotherapy Drug Production (2018-2029)
1.3.7 Japan Cancer Immunotherapy Drug Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Cancer Immunotherapy Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Cancer Immunotherapy Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Cancer Immunotherapy Drug Demand (2018-2029)
2.2 World Cancer Immunotherapy Drug Consumption by Region
2.2.1 World Cancer Immunotherapy Drug Consumption by Region (2018-2023)
2.2.2 World Cancer Immunotherapy Drug Consumption Forecast by Region (2024-2029)
2.3 United States Cancer Immunotherapy Drug Consumption (2018-2029)
2.4 China Cancer Immunotherapy Drug Consumption (2018-2029)
2.5 Europe Cancer Immunotherapy Drug Consumption (2018-2029)
2.6 Japan Cancer Immunotherapy Drug Consumption (2018-2029)
2.7 South Korea Cancer Immunotherapy Drug Consumption (2018-2029)
2.8 ASEAN Cancer Immunotherapy Drug Consumption (2018-2029)
2.9 India Cancer Immunotherapy Drug Consumption (2018-2029)
3 WORLD CANCER IMMUNOTHERAPY DRUG MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Cancer Immunotherapy Drug Production Value by Manufacturer (2018-2023)
3.2 World Cancer Immunotherapy Drug Production by Manufacturer (2018-2023)
3.3 World Cancer Immunotherapy Drug Average Price by Manufacturer (2018-2023)
3.4 Cancer Immunotherapy Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Cancer Immunotherapy Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Cancer Immunotherapy Drug in 2022
3.5.3 Global Concentration Ratios (CR8) for Cancer Immunotherapy Drug in 2022
3.6 Cancer Immunotherapy Drug Market: Overall Company Footprint Analysis
3.6.1 Cancer Immunotherapy Drug Market: Region Footprint
3.6.2 Cancer Immunotherapy Drug Market: Company Product Type Footprint
3.6.3 Cancer Immunotherapy Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Cancer Immunotherapy Drug Production Value Comparison
4.1.1 United States VS China: Cancer Immunotherapy Drug Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Cancer Immunotherapy Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Cancer Immunotherapy Drug Production Comparison
4.2.1 United States VS China: Cancer Immunotherapy Drug Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Cancer Immunotherapy Drug Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Cancer Immunotherapy Drug Consumption Comparison
4.3.1 United States VS China: Cancer Immunotherapy Drug Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Cancer Immunotherapy Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Cancer Immunotherapy Drug Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Cancer Immunotherapy Drug Production Value (2018-2023)
4.4.3 United States Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023)
4.5 China Based Cancer Immunotherapy Drug Manufacturers and Market Share
4.5.1 China Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Cancer Immunotherapy Drug Production Value (2018-2023)
4.5.3 China Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023)
4.6 Rest of World Based Cancer Immunotherapy Drug Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Cancer Immunotherapy Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 PD-1 Inhibitor
5.2.2 PDL-1 Inhibitor
5.2.3 T-Cell Stimulant
5.2.4 CTLA Antibody
5.3 Market Segment by Type
5.3.1 World Cancer Immunotherapy Drug Production by Type (2018-2029)
5.3.2 World Cancer Immunotherapy Drug Production Value by Type (2018-2029)
5.3.3 World Cancer Immunotherapy Drug Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Cancer Immunotherapy Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Cancer Immunotherapy Drug Production by Application (2018-2029)
6.3.2 World Cancer Immunotherapy Drug Production Value by Application (2018-2029)
6.3.3 World Cancer Immunotherapy Drug Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Autolus Therapeutics plc
7.1.1 Autolus Therapeutics plc Details
7.1.2 Autolus Therapeutics plc Major Business
7.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Product and Services
7.1.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Autolus Therapeutics plc Recent Developments/Updates
7.1.6 Autolus Therapeutics plc Competitive Strengths & Weaknesses
7.2 BeiGene
7.2.1 BeiGene Details
7.2.2 BeiGene Major Business
7.2.3 BeiGene Cancer Immunotherapy Drug Product and Services
7.2.4 BeiGene Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 BeiGene Recent Developments/Updates
7.2.6 BeiGene Competitive Strengths & Weaknesses
7.3 bluebird bio, Inc.
7.3.1 bluebird bio, Inc. Details
7.3.2 bluebird bio, Inc. Major Business
7.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Product and Services
7.3.4 bluebird bio, Inc. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 bluebird bio, Inc. Recent Developments/Updates
7.3.6 bluebird bio, Inc. Competitive Strengths & Weaknesses
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Details
7.4.2 Bristol-Myers Squibb Major Business
7.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Product and Services
7.4.4 Bristol-Myers Squibb Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Bristol-Myers Squibb Recent Developments/Updates
7.4.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.5 Celgene Corporation
7.5.1 Celgene Corporation Details
7.5.2 Celgene Corporation Major Business
7.5.3 Celgene Corporation Cancer Immunotherapy Drug Product and Services
7.5.4 Celgene Corporation Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Celgene Corporation Recent Developments/Updates
7.5.6 Celgene Corporation Competitive Strengths & Weaknesses
7.6 AstraZeneca plc
7.6.1 AstraZeneca plc Details
7.6.2 AstraZeneca plc Major Business
7.6.3 AstraZeneca plc Cancer Immunotherapy Drug Product and Services
7.6.4 AstraZeneca plc Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 AstraZeneca plc Recent Developments/Updates
7.6.6 AstraZeneca plc Competitive Strengths & Weaknesses
7.7 Gilead Sciences, Inc.
7.7.1 Gilead Sciences, Inc. Details
7.7.2 Gilead Sciences, Inc. Major Business
7.7.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product and Services
7.7.4 Gilead Sciences, Inc. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Gilead Sciences, Inc. Recent Developments/Updates
7.7.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
7.8 Incyte Corporation
7.8.1 Incyte Corporation Details
7.8.2 Incyte Corporation Major Business
7.8.3 Incyte Corporation Cancer Immunotherapy Drug Product and Services
7.8.4 Incyte Corporation Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Incyte Corporation Recent Developments/Updates
7.8.6 Incyte Corporation Competitive Strengths & Weaknesses
7.9 Jiangsu Hengrui Medicine
7.9.1 Jiangsu Hengrui Medicine Details
7.9.2 Jiangsu Hengrui Medicine Major Business
7.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product and Services
7.9.4 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Jiangsu Hengrui Medicine Recent Developments/Updates
7.9.6 Jiangsu Hengrui Medicine Competitive Strengths & Weaknesses
7.10 Juno Pharmaceuticals Pty Ltd.
7.10.1 Juno Pharmaceuticals Pty Ltd. Details
7.10.2 Juno Pharmaceuticals Pty Ltd. Major Business
7.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product and Services
7.10.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
7.10.6 Juno Pharmaceuticals Pty Ltd. Competitive Strengths & Weaknesses
7.11 Medimmune, LLC
7.11.1 Medimmune, LLC Details
7.11.2 Medimmune, LLC Major Business
7.11.3 Medimmune, LLC Cancer Immunotherapy Drug Product and Services
7.11.4 Medimmune, LLC Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Medimmune, LLC Recent Developments/Updates
7.11.6 Medimmune, LLC Competitive Strengths & Weaknesses
7.12 Merck & Co., Inc.
7.12.1 Merck & Co., Inc. Details
7.12.2 Merck & Co., Inc. Major Business
7.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Product and Services
7.12.4 Merck & Co., Inc. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Merck & Co., Inc. Recent Developments/Updates
7.12.6 Merck & Co., Inc. Competitive Strengths & Weaknesses
7.13 Novartis AG
7.13.1 Novartis AG Details
7.13.2 Novartis AG Major Business
7.13.3 Novartis AG Cancer Immunotherapy Drug Product and Services
7.13.4 Novartis AG Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.13.5 Novartis AG Recent Developments/Updates
7.13.6 Novartis AG Competitive Strengths & Weaknesses
7.14 Pfizer, Inc.
7.14.1 Pfizer, Inc. Details
7.14.2 Pfizer, Inc. Major Business
7.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Product and Services
7.14.4 Pfizer, Inc. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.14.5 Pfizer, Inc. Recent Developments/Updates
7.14.6 Pfizer, Inc. Competitive Strengths & Weaknesses
7.15 Roche Holding AG
7.15.1 Roche Holding AG Details
7.15.2 Roche Holding AG Major Business
7.15.3 Roche Holding AG Cancer Immunotherapy Drug Product and Services
7.15.4 Roche Holding AG Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.15.5 Roche Holding AG Recent Developments/Updates
7.15.6 Roche Holding AG Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Cancer Immunotherapy Drug Industry Chain
8.2 Cancer Immunotherapy Drug Upstream Analysis
8.2.1 Cancer Immunotherapy Drug Core Raw Materials
8.2.2 Main Manufacturers of Cancer Immunotherapy Drug Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Cancer Immunotherapy Drug Production Mode
8.6 Cancer Immunotherapy Drug Procurement Model
8.7 Cancer Immunotherapy Drug Industry Sales Model and Sales Channels
8.7.1 Cancer Immunotherapy Drug Sales Model
8.7.2 Cancer Immunotherapy Drug Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Cancer Immunotherapy Drug Introduction
1.2 World Cancer Immunotherapy Drug Supply & Forecast
1.2.1 World Cancer Immunotherapy Drug Production Value (2018 & 2022 & 2029)
1.2.2 World Cancer Immunotherapy Drug Production (2018-2029)
1.2.3 World Cancer Immunotherapy Drug Pricing Trends (2018-2029)
1.3 World Cancer Immunotherapy Drug Production by Region (Based on Production Site)
1.3.1 World Cancer Immunotherapy Drug Production Value by Region (2018-2029)
1.3.2 World Cancer Immunotherapy Drug Production by Region (2018-2029)
1.3.3 World Cancer Immunotherapy Drug Average Price by Region (2018-2029)
1.3.4 North America Cancer Immunotherapy Drug Production (2018-2029)
1.3.5 Europe Cancer Immunotherapy Drug Production (2018-2029)
1.3.6 China Cancer Immunotherapy Drug Production (2018-2029)
1.3.7 Japan Cancer Immunotherapy Drug Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Cancer Immunotherapy Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Cancer Immunotherapy Drug Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Cancer Immunotherapy Drug Demand (2018-2029)
2.2 World Cancer Immunotherapy Drug Consumption by Region
2.2.1 World Cancer Immunotherapy Drug Consumption by Region (2018-2023)
2.2.2 World Cancer Immunotherapy Drug Consumption Forecast by Region (2024-2029)
2.3 United States Cancer Immunotherapy Drug Consumption (2018-2029)
2.4 China Cancer Immunotherapy Drug Consumption (2018-2029)
2.5 Europe Cancer Immunotherapy Drug Consumption (2018-2029)
2.6 Japan Cancer Immunotherapy Drug Consumption (2018-2029)
2.7 South Korea Cancer Immunotherapy Drug Consumption (2018-2029)
2.8 ASEAN Cancer Immunotherapy Drug Consumption (2018-2029)
2.9 India Cancer Immunotherapy Drug Consumption (2018-2029)
3 WORLD CANCER IMMUNOTHERAPY DRUG MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Cancer Immunotherapy Drug Production Value by Manufacturer (2018-2023)
3.2 World Cancer Immunotherapy Drug Production by Manufacturer (2018-2023)
3.3 World Cancer Immunotherapy Drug Average Price by Manufacturer (2018-2023)
3.4 Cancer Immunotherapy Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Cancer Immunotherapy Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Cancer Immunotherapy Drug in 2022
3.5.3 Global Concentration Ratios (CR8) for Cancer Immunotherapy Drug in 2022
3.6 Cancer Immunotherapy Drug Market: Overall Company Footprint Analysis
3.6.1 Cancer Immunotherapy Drug Market: Region Footprint
3.6.2 Cancer Immunotherapy Drug Market: Company Product Type Footprint
3.6.3 Cancer Immunotherapy Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Cancer Immunotherapy Drug Production Value Comparison
4.1.1 United States VS China: Cancer Immunotherapy Drug Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Cancer Immunotherapy Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Cancer Immunotherapy Drug Production Comparison
4.2.1 United States VS China: Cancer Immunotherapy Drug Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Cancer Immunotherapy Drug Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Cancer Immunotherapy Drug Consumption Comparison
4.3.1 United States VS China: Cancer Immunotherapy Drug Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Cancer Immunotherapy Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Cancer Immunotherapy Drug Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Cancer Immunotherapy Drug Production Value (2018-2023)
4.4.3 United States Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023)
4.5 China Based Cancer Immunotherapy Drug Manufacturers and Market Share
4.5.1 China Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Cancer Immunotherapy Drug Production Value (2018-2023)
4.5.3 China Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023)
4.6 Rest of World Based Cancer Immunotherapy Drug Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Cancer Immunotherapy Drug Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 PD-1 Inhibitor
5.2.2 PDL-1 Inhibitor
5.2.3 T-Cell Stimulant
5.2.4 CTLA Antibody
5.3 Market Segment by Type
5.3.1 World Cancer Immunotherapy Drug Production by Type (2018-2029)
5.3.2 World Cancer Immunotherapy Drug Production Value by Type (2018-2029)
5.3.3 World Cancer Immunotherapy Drug Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Cancer Immunotherapy Drug Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Cancer Immunotherapy Drug Production by Application (2018-2029)
6.3.2 World Cancer Immunotherapy Drug Production Value by Application (2018-2029)
6.3.3 World Cancer Immunotherapy Drug Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Autolus Therapeutics plc
7.1.1 Autolus Therapeutics plc Details
7.1.2 Autolus Therapeutics plc Major Business
7.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Product and Services
7.1.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Autolus Therapeutics plc Recent Developments/Updates
7.1.6 Autolus Therapeutics plc Competitive Strengths & Weaknesses
7.2 BeiGene
7.2.1 BeiGene Details
7.2.2 BeiGene Major Business
7.2.3 BeiGene Cancer Immunotherapy Drug Product and Services
7.2.4 BeiGene Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 BeiGene Recent Developments/Updates
7.2.6 BeiGene Competitive Strengths & Weaknesses
7.3 bluebird bio, Inc.
7.3.1 bluebird bio, Inc. Details
7.3.2 bluebird bio, Inc. Major Business
7.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Product and Services
7.3.4 bluebird bio, Inc. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 bluebird bio, Inc. Recent Developments/Updates
7.3.6 bluebird bio, Inc. Competitive Strengths & Weaknesses
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Details
7.4.2 Bristol-Myers Squibb Major Business
7.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Product and Services
7.4.4 Bristol-Myers Squibb Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Bristol-Myers Squibb Recent Developments/Updates
7.4.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.5 Celgene Corporation
7.5.1 Celgene Corporation Details
7.5.2 Celgene Corporation Major Business
7.5.3 Celgene Corporation Cancer Immunotherapy Drug Product and Services
7.5.4 Celgene Corporation Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Celgene Corporation Recent Developments/Updates
7.5.6 Celgene Corporation Competitive Strengths & Weaknesses
7.6 AstraZeneca plc
7.6.1 AstraZeneca plc Details
7.6.2 AstraZeneca plc Major Business
7.6.3 AstraZeneca plc Cancer Immunotherapy Drug Product and Services
7.6.4 AstraZeneca plc Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 AstraZeneca plc Recent Developments/Updates
7.6.6 AstraZeneca plc Competitive Strengths & Weaknesses
7.7 Gilead Sciences, Inc.
7.7.1 Gilead Sciences, Inc. Details
7.7.2 Gilead Sciences, Inc. Major Business
7.7.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product and Services
7.7.4 Gilead Sciences, Inc. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Gilead Sciences, Inc. Recent Developments/Updates
7.7.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
7.8 Incyte Corporation
7.8.1 Incyte Corporation Details
7.8.2 Incyte Corporation Major Business
7.8.3 Incyte Corporation Cancer Immunotherapy Drug Product and Services
7.8.4 Incyte Corporation Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Incyte Corporation Recent Developments/Updates
7.8.6 Incyte Corporation Competitive Strengths & Weaknesses
7.9 Jiangsu Hengrui Medicine
7.9.1 Jiangsu Hengrui Medicine Details
7.9.2 Jiangsu Hengrui Medicine Major Business
7.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product and Services
7.9.4 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Jiangsu Hengrui Medicine Recent Developments/Updates
7.9.6 Jiangsu Hengrui Medicine Competitive Strengths & Weaknesses
7.10 Juno Pharmaceuticals Pty Ltd.
7.10.1 Juno Pharmaceuticals Pty Ltd. Details
7.10.2 Juno Pharmaceuticals Pty Ltd. Major Business
7.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product and Services
7.10.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
7.10.6 Juno Pharmaceuticals Pty Ltd. Competitive Strengths & Weaknesses
7.11 Medimmune, LLC
7.11.1 Medimmune, LLC Details
7.11.2 Medimmune, LLC Major Business
7.11.3 Medimmune, LLC Cancer Immunotherapy Drug Product and Services
7.11.4 Medimmune, LLC Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.11.5 Medimmune, LLC Recent Developments/Updates
7.11.6 Medimmune, LLC Competitive Strengths & Weaknesses
7.12 Merck & Co., Inc.
7.12.1 Merck & Co., Inc. Details
7.12.2 Merck & Co., Inc. Major Business
7.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Product and Services
7.12.4 Merck & Co., Inc. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.12.5 Merck & Co., Inc. Recent Developments/Updates
7.12.6 Merck & Co., Inc. Competitive Strengths & Weaknesses
7.13 Novartis AG
7.13.1 Novartis AG Details
7.13.2 Novartis AG Major Business
7.13.3 Novartis AG Cancer Immunotherapy Drug Product and Services
7.13.4 Novartis AG Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.13.5 Novartis AG Recent Developments/Updates
7.13.6 Novartis AG Competitive Strengths & Weaknesses
7.14 Pfizer, Inc.
7.14.1 Pfizer, Inc. Details
7.14.2 Pfizer, Inc. Major Business
7.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Product and Services
7.14.4 Pfizer, Inc. Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.14.5 Pfizer, Inc. Recent Developments/Updates
7.14.6 Pfizer, Inc. Competitive Strengths & Weaknesses
7.15 Roche Holding AG
7.15.1 Roche Holding AG Details
7.15.2 Roche Holding AG Major Business
7.15.3 Roche Holding AG Cancer Immunotherapy Drug Product and Services
7.15.4 Roche Holding AG Cancer Immunotherapy Drug Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.15.5 Roche Holding AG Recent Developments/Updates
7.15.6 Roche Holding AG Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Cancer Immunotherapy Drug Industry Chain
8.2 Cancer Immunotherapy Drug Upstream Analysis
8.2.1 Cancer Immunotherapy Drug Core Raw Materials
8.2.2 Main Manufacturers of Cancer Immunotherapy Drug Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Cancer Immunotherapy Drug Production Mode
8.6 Cancer Immunotherapy Drug Procurement Model
8.7 Cancer Immunotherapy Drug Industry Sales Model and Sales Channels
8.7.1 Cancer Immunotherapy Drug Sales Model
8.7.2 Cancer Immunotherapy Drug Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Cancer Immunotherapy Drug Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Cancer Immunotherapy Drug Production Value by Region (2018-2023) & (USD Million)
Table 3. World Cancer Immunotherapy Drug Production Value by Region (2024-2029) & (USD Million)
Table 4. World Cancer Immunotherapy Drug Production Value Market Share by Region (2018-2023)
Table 5. World Cancer Immunotherapy Drug Production Value Market Share by Region (2024-2029)
Table 6. World Cancer Immunotherapy Drug Production by Region (2018-2023) & (K Units)
Table 7. World Cancer Immunotherapy Drug Production by Region (2024-2029) & (K Units)
Table 8. World Cancer Immunotherapy Drug Production Market Share by Region (2018-2023)
Table 9. World Cancer Immunotherapy Drug Production Market Share by Region (2024-2029)
Table 10. World Cancer Immunotherapy Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Cancer Immunotherapy Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Cancer Immunotherapy Drug Major Market Trends
Table 13. World Cancer Immunotherapy Drug Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Cancer Immunotherapy Drug Consumption by Region (2018-2023) & (K Units)
Table 15. World Cancer Immunotherapy Drug Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Cancer Immunotherapy Drug Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Cancer Immunotherapy Drug Producers in 2022
Table 18. World Cancer Immunotherapy Drug Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Cancer Immunotherapy Drug Producers in 2022
Table 20. World Cancer Immunotherapy Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Cancer Immunotherapy Drug Company Evaluation Quadrant
Table 22. World Cancer Immunotherapy Drug Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Cancer Immunotherapy Drug Production Site of Key Manufacturer
Table 24. Cancer Immunotherapy Drug Market: Company Product Type Footprint
Table 25. Cancer Immunotherapy Drug Market: Company Product Application Footprint
Table 26. Cancer Immunotherapy Drug Competitive Factors
Table 27. Cancer Immunotherapy Drug New Entrant and Capacity Expansion Plans
Table 28. Cancer Immunotherapy Drug Mergers & Acquisitions Activity
Table 29. United States VS China Cancer Immunotherapy Drug Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Cancer Immunotherapy Drug Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Cancer Immunotherapy Drug Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Cancer Immunotherapy Drug Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Cancer Immunotherapy Drug Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Cancer Immunotherapy Drug Production Market Share (2018-2023)
Table 37. China Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Cancer Immunotherapy Drug Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Cancer Immunotherapy Drug Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Cancer Immunotherapy Drug Production Market Share (2018-2023)
Table 42. Rest of World Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Market Share (2018-2023)
Table 47. World Cancer Immunotherapy Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Cancer Immunotherapy Drug Production by Type (2018-2023) & (K Units)
Table 49. World Cancer Immunotherapy Drug Production by Type (2024-2029) & (K Units)
Table 50. World Cancer Immunotherapy Drug Production Value by Type (2018-2023) & (USD Million)
Table 51. World Cancer Immunotherapy Drug Production Value by Type (2024-2029) & (USD Million)
Table 52. World Cancer Immunotherapy Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Cancer Immunotherapy Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Cancer Immunotherapy Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Cancer Immunotherapy Drug Production by Application (2018-2023) & (K Units)
Table 56. World Cancer Immunotherapy Drug Production by Application (2024-2029) & (K Units)
Table 57. World Cancer Immunotherapy Drug Production Value by Application (2018-2023) & (USD Million)
Table 58. World Cancer Immunotherapy Drug Production Value by Application (2024-2029) & (USD Million)
Table 59. World Cancer Immunotherapy Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Cancer Immunotherapy Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Autolus Therapeutics plc Basic Information, Manufacturing Base and Competitors
Table 62. Autolus Therapeutics plc Major Business
Table 63. Autolus Therapeutics plc Cancer Immunotherapy Drug Product and Services
Table 64. Autolus Therapeutics plc Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Autolus Therapeutics plc Recent Developments/Updates
Table 66. Autolus Therapeutics plc Competitive Strengths & Weaknesses
Table 67. BeiGene Basic Information, Manufacturing Base and Competitors
Table 68. BeiGene Major Business
Table 69. BeiGene Cancer Immunotherapy Drug Product and Services
Table 70. BeiGene Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. BeiGene Recent Developments/Updates
Table 72. BeiGene Competitive Strengths & Weaknesses
Table 73. bluebird bio, Inc. Basic Information, Manufacturing Base and Competitors
Table 74. bluebird bio, Inc. Major Business
Table 75. bluebird bio, Inc. Cancer Immunotherapy Drug Product and Services
Table 76. bluebird bio, Inc. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. bluebird bio, Inc. Recent Developments/Updates
Table 78. bluebird bio, Inc. Competitive Strengths & Weaknesses
Table 79. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 80. Bristol-Myers Squibb Major Business
Table 81. Bristol-Myers Squibb Cancer Immunotherapy Drug Product and Services
Table 82. Bristol-Myers Squibb Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Bristol-Myers Squibb Recent Developments/Updates
Table 84. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 85. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 86. Celgene Corporation Major Business
Table 87. Celgene Corporation Cancer Immunotherapy Drug Product and Services
Table 88. Celgene Corporation Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Celgene Corporation Recent Developments/Updates
Table 90. Celgene Corporation Competitive Strengths & Weaknesses
Table 91. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 92. AstraZeneca plc Major Business
Table 93. AstraZeneca plc Cancer Immunotherapy Drug Product and Services
Table 94. AstraZeneca plc Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. AstraZeneca plc Recent Developments/Updates
Table 96. AstraZeneca plc Competitive Strengths & Weaknesses
Table 97. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 98. Gilead Sciences, Inc. Major Business
Table 99. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product and Services
Table 100. Gilead Sciences, Inc. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Gilead Sciences, Inc. Recent Developments/Updates
Table 102. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 103. Incyte Corporation Basic Information, Manufacturing Base and Competitors
Table 104. Incyte Corporation Major Business
Table 105. Incyte Corporation Cancer Immunotherapy Drug Product and Services
Table 106. Incyte Corporation Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Incyte Corporation Recent Developments/Updates
Table 108. Incyte Corporation Competitive Strengths & Weaknesses
Table 109. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table 110. Jiangsu Hengrui Medicine Major Business
Table 111. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product and Services
Table 112. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 114. Jiangsu Hengrui Medicine Competitive Strengths & Weaknesses
Table 115. Juno Pharmaceuticals Pty Ltd. Basic Information, Manufacturing Base and Competitors
Table 116. Juno Pharmaceuticals Pty Ltd. Major Business
Table 117. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product and Services
Table 118. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
Table 120. Juno Pharmaceuticals Pty Ltd. Competitive Strengths & Weaknesses
Table 121. Medimmune, LLC Basic Information, Manufacturing Base and Competitors
Table 122. Medimmune, LLC Major Business
Table 123. Medimmune, LLC Cancer Immunotherapy Drug Product and Services
Table 124. Medimmune, LLC Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Medimmune, LLC Recent Developments/Updates
Table 126. Medimmune, LLC Competitive Strengths & Weaknesses
Table 127. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 128. Merck & Co., Inc. Major Business
Table 129. Merck & Co., Inc. Cancer Immunotherapy Drug Product and Services
Table 130. Merck & Co., Inc. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 131. Merck & Co., Inc. Recent Developments/Updates
Table 132. Merck & Co., Inc. Competitive Strengths & Weaknesses
Table 133. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 134. Novartis AG Major Business
Table 135. Novartis AG Cancer Immunotherapy Drug Product and Services
Table 136. Novartis AG Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 137. Novartis AG Recent Developments/Updates
Table 138. Novartis AG Competitive Strengths & Weaknesses
Table 139. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 140. Pfizer, Inc. Major Business
Table 141. Pfizer, Inc. Cancer Immunotherapy Drug Product and Services
Table 142. Pfizer, Inc. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 143. Pfizer, Inc. Recent Developments/Updates
Table 144. Roche Holding AG Basic Information, Manufacturing Base and Competitors
Table 145. Roche Holding AG Major Business
Table 146. Roche Holding AG Cancer Immunotherapy Drug Product and Services
Table 147. Roche Holding AG Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 148. Global Key Players of Cancer Immunotherapy Drug Upstream (Raw Materials)
Table 149. Cancer Immunotherapy Drug Typical Customers
Table 150. Cancer Immunotherapy Drug Typical Distributors
Table 1. World Cancer Immunotherapy Drug Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Cancer Immunotherapy Drug Production Value by Region (2018-2023) & (USD Million)
Table 3. World Cancer Immunotherapy Drug Production Value by Region (2024-2029) & (USD Million)
Table 4. World Cancer Immunotherapy Drug Production Value Market Share by Region (2018-2023)
Table 5. World Cancer Immunotherapy Drug Production Value Market Share by Region (2024-2029)
Table 6. World Cancer Immunotherapy Drug Production by Region (2018-2023) & (K Units)
Table 7. World Cancer Immunotherapy Drug Production by Region (2024-2029) & (K Units)
Table 8. World Cancer Immunotherapy Drug Production Market Share by Region (2018-2023)
Table 9. World Cancer Immunotherapy Drug Production Market Share by Region (2024-2029)
Table 10. World Cancer Immunotherapy Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Cancer Immunotherapy Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Cancer Immunotherapy Drug Major Market Trends
Table 13. World Cancer Immunotherapy Drug Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Cancer Immunotherapy Drug Consumption by Region (2018-2023) & (K Units)
Table 15. World Cancer Immunotherapy Drug Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Cancer Immunotherapy Drug Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Cancer Immunotherapy Drug Producers in 2022
Table 18. World Cancer Immunotherapy Drug Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Cancer Immunotherapy Drug Producers in 2022
Table 20. World Cancer Immunotherapy Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Cancer Immunotherapy Drug Company Evaluation Quadrant
Table 22. World Cancer Immunotherapy Drug Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Cancer Immunotherapy Drug Production Site of Key Manufacturer
Table 24. Cancer Immunotherapy Drug Market: Company Product Type Footprint
Table 25. Cancer Immunotherapy Drug Market: Company Product Application Footprint
Table 26. Cancer Immunotherapy Drug Competitive Factors
Table 27. Cancer Immunotherapy Drug New Entrant and Capacity Expansion Plans
Table 28. Cancer Immunotherapy Drug Mergers & Acquisitions Activity
Table 29. United States VS China Cancer Immunotherapy Drug Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Cancer Immunotherapy Drug Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Cancer Immunotherapy Drug Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Cancer Immunotherapy Drug Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Cancer Immunotherapy Drug Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Cancer Immunotherapy Drug Production Market Share (2018-2023)
Table 37. China Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Cancer Immunotherapy Drug Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Cancer Immunotherapy Drug Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Cancer Immunotherapy Drug Production Market Share (2018-2023)
Table 42. Rest of World Based Cancer Immunotherapy Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Market Share (2018-2023)
Table 47. World Cancer Immunotherapy Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Cancer Immunotherapy Drug Production by Type (2018-2023) & (K Units)
Table 49. World Cancer Immunotherapy Drug Production by Type (2024-2029) & (K Units)
Table 50. World Cancer Immunotherapy Drug Production Value by Type (2018-2023) & (USD Million)
Table 51. World Cancer Immunotherapy Drug Production Value by Type (2024-2029) & (USD Million)
Table 52. World Cancer Immunotherapy Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Cancer Immunotherapy Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Cancer Immunotherapy Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Cancer Immunotherapy Drug Production by Application (2018-2023) & (K Units)
Table 56. World Cancer Immunotherapy Drug Production by Application (2024-2029) & (K Units)
Table 57. World Cancer Immunotherapy Drug Production Value by Application (2018-2023) & (USD Million)
Table 58. World Cancer Immunotherapy Drug Production Value by Application (2024-2029) & (USD Million)
Table 59. World Cancer Immunotherapy Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Cancer Immunotherapy Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Autolus Therapeutics plc Basic Information, Manufacturing Base and Competitors
Table 62. Autolus Therapeutics plc Major Business
Table 63. Autolus Therapeutics plc Cancer Immunotherapy Drug Product and Services
Table 64. Autolus Therapeutics plc Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Autolus Therapeutics plc Recent Developments/Updates
Table 66. Autolus Therapeutics plc Competitive Strengths & Weaknesses
Table 67. BeiGene Basic Information, Manufacturing Base and Competitors
Table 68. BeiGene Major Business
Table 69. BeiGene Cancer Immunotherapy Drug Product and Services
Table 70. BeiGene Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. BeiGene Recent Developments/Updates
Table 72. BeiGene Competitive Strengths & Weaknesses
Table 73. bluebird bio, Inc. Basic Information, Manufacturing Base and Competitors
Table 74. bluebird bio, Inc. Major Business
Table 75. bluebird bio, Inc. Cancer Immunotherapy Drug Product and Services
Table 76. bluebird bio, Inc. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. bluebird bio, Inc. Recent Developments/Updates
Table 78. bluebird bio, Inc. Competitive Strengths & Weaknesses
Table 79. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 80. Bristol-Myers Squibb Major Business
Table 81. Bristol-Myers Squibb Cancer Immunotherapy Drug Product and Services
Table 82. Bristol-Myers Squibb Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Bristol-Myers Squibb Recent Developments/Updates
Table 84. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 85. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 86. Celgene Corporation Major Business
Table 87. Celgene Corporation Cancer Immunotherapy Drug Product and Services
Table 88. Celgene Corporation Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Celgene Corporation Recent Developments/Updates
Table 90. Celgene Corporation Competitive Strengths & Weaknesses
Table 91. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 92. AstraZeneca plc Major Business
Table 93. AstraZeneca plc Cancer Immunotherapy Drug Product and Services
Table 94. AstraZeneca plc Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. AstraZeneca plc Recent Developments/Updates
Table 96. AstraZeneca plc Competitive Strengths & Weaknesses
Table 97. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 98. Gilead Sciences, Inc. Major Business
Table 99. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product and Services
Table 100. Gilead Sciences, Inc. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Gilead Sciences, Inc. Recent Developments/Updates
Table 102. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 103. Incyte Corporation Basic Information, Manufacturing Base and Competitors
Table 104. Incyte Corporation Major Business
Table 105. Incyte Corporation Cancer Immunotherapy Drug Product and Services
Table 106. Incyte Corporation Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Incyte Corporation Recent Developments/Updates
Table 108. Incyte Corporation Competitive Strengths & Weaknesses
Table 109. Jiangsu Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table 110. Jiangsu Hengrui Medicine Major Business
Table 111. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product and Services
Table 112. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Jiangsu Hengrui Medicine Recent Developments/Updates
Table 114. Jiangsu Hengrui Medicine Competitive Strengths & Weaknesses
Table 115. Juno Pharmaceuticals Pty Ltd. Basic Information, Manufacturing Base and Competitors
Table 116. Juno Pharmaceuticals Pty Ltd. Major Business
Table 117. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product and Services
Table 118. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 119. Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
Table 120. Juno Pharmaceuticals Pty Ltd. Competitive Strengths & Weaknesses
Table 121. Medimmune, LLC Basic Information, Manufacturing Base and Competitors
Table 122. Medimmune, LLC Major Business
Table 123. Medimmune, LLC Cancer Immunotherapy Drug Product and Services
Table 124. Medimmune, LLC Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 125. Medimmune, LLC Recent Developments/Updates
Table 126. Medimmune, LLC Competitive Strengths & Weaknesses
Table 127. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 128. Merck & Co., Inc. Major Business
Table 129. Merck & Co., Inc. Cancer Immunotherapy Drug Product and Services
Table 130. Merck & Co., Inc. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 131. Merck & Co., Inc. Recent Developments/Updates
Table 132. Merck & Co., Inc. Competitive Strengths & Weaknesses
Table 133. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 134. Novartis AG Major Business
Table 135. Novartis AG Cancer Immunotherapy Drug Product and Services
Table 136. Novartis AG Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 137. Novartis AG Recent Developments/Updates
Table 138. Novartis AG Competitive Strengths & Weaknesses
Table 139. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 140. Pfizer, Inc. Major Business
Table 141. Pfizer, Inc. Cancer Immunotherapy Drug Product and Services
Table 142. Pfizer, Inc. Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 143. Pfizer, Inc. Recent Developments/Updates
Table 144. Roche Holding AG Basic Information, Manufacturing Base and Competitors
Table 145. Roche Holding AG Major Business
Table 146. Roche Holding AG Cancer Immunotherapy Drug Product and Services
Table 147. Roche Holding AG Cancer Immunotherapy Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 148. Global Key Players of Cancer Immunotherapy Drug Upstream (Raw Materials)
Table 149. Cancer Immunotherapy Drug Typical Customers
Table 150. Cancer Immunotherapy Drug Typical Distributors
LIST OF FIGURES
Figure 1. Cancer Immunotherapy Drug Picture
Figure 2. World Cancer Immunotherapy Drug Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Cancer Immunotherapy Drug Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 5. World Cancer Immunotherapy Drug Average Price (2018-2029) & (US$/Unit)
Figure 6. World Cancer Immunotherapy Drug Production Value Market Share by Region (2018-2029)
Figure 7. World Cancer Immunotherapy Drug Production Market Share by Region (2018-2029)
Figure 8. North America Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 9. Europe Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 10. China Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 11. Japan Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 12. Cancer Immunotherapy Drug Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 15. World Cancer Immunotherapy Drug Consumption Market Share by Region (2018-2029)
Figure 16. United States Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 17. China Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 18. Europe Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 19. Japan Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 20. South Korea Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 22. India Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Cancer Immunotherapy Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Cancer Immunotherapy Drug Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Cancer Immunotherapy Drug Markets in 2022
Figure 26. United States VS China: Cancer Immunotherapy Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Cancer Immunotherapy Drug Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Cancer Immunotherapy Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Cancer Immunotherapy Drug Production Market Share 2022
Figure 30. China Based Manufacturers Cancer Immunotherapy Drug Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Market Share 2022
Figure 32. World Cancer Immunotherapy Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Cancer Immunotherapy Drug Production Value Market Share by Type in 2022
Figure 34. PD-1 Inhibitor
Figure 35. PDL-1 Inhibitor
Figure 36. T-Cell Stimulant
Figure 37. CTLA Antibody
Figure 38. World Cancer Immunotherapy Drug Production Market Share by Type (2018-2029)
Figure 39. World Cancer Immunotherapy Drug Production Value Market Share by Type (2018-2029)
Figure 40. World Cancer Immunotherapy Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 41. World Cancer Immunotherapy Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 42. World Cancer Immunotherapy Drug Production Value Market Share by Application in 2022
Figure 43. Hospital
Figure 44. Clinic
Figure 45. Others
Figure 46. World Cancer Immunotherapy Drug Production Market Share by Application (2018-2029)
Figure 47. World Cancer Immunotherapy Drug Production Value Market Share by Application (2018-2029)
Figure 48. World Cancer Immunotherapy Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Cancer Immunotherapy Drug Industry Chain
Figure 50. Cancer Immunotherapy Drug Procurement Model
Figure 51. Cancer Immunotherapy Drug Sales Model
Figure 52. Cancer Immunotherapy Drug Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
Figure 1. Cancer Immunotherapy Drug Picture
Figure 2. World Cancer Immunotherapy Drug Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Cancer Immunotherapy Drug Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 5. World Cancer Immunotherapy Drug Average Price (2018-2029) & (US$/Unit)
Figure 6. World Cancer Immunotherapy Drug Production Value Market Share by Region (2018-2029)
Figure 7. World Cancer Immunotherapy Drug Production Market Share by Region (2018-2029)
Figure 8. North America Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 9. Europe Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 10. China Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 11. Japan Cancer Immunotherapy Drug Production (2018-2029) & (K Units)
Figure 12. Cancer Immunotherapy Drug Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 15. World Cancer Immunotherapy Drug Consumption Market Share by Region (2018-2029)
Figure 16. United States Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 17. China Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 18. Europe Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 19. Japan Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 20. South Korea Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 22. India Cancer Immunotherapy Drug Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Cancer Immunotherapy Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Cancer Immunotherapy Drug Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Cancer Immunotherapy Drug Markets in 2022
Figure 26. United States VS China: Cancer Immunotherapy Drug Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Cancer Immunotherapy Drug Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Cancer Immunotherapy Drug Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Cancer Immunotherapy Drug Production Market Share 2022
Figure 30. China Based Manufacturers Cancer Immunotherapy Drug Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Cancer Immunotherapy Drug Production Market Share 2022
Figure 32. World Cancer Immunotherapy Drug Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Cancer Immunotherapy Drug Production Value Market Share by Type in 2022
Figure 34. PD-1 Inhibitor
Figure 35. PDL-1 Inhibitor
Figure 36. T-Cell Stimulant
Figure 37. CTLA Antibody
Figure 38. World Cancer Immunotherapy Drug Production Market Share by Type (2018-2029)
Figure 39. World Cancer Immunotherapy Drug Production Value Market Share by Type (2018-2029)
Figure 40. World Cancer Immunotherapy Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 41. World Cancer Immunotherapy Drug Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 42. World Cancer Immunotherapy Drug Production Value Market Share by Application in 2022
Figure 43. Hospital
Figure 44. Clinic
Figure 45. Others
Figure 46. World Cancer Immunotherapy Drug Production Market Share by Application (2018-2029)
Figure 47. World Cancer Immunotherapy Drug Production Value Market Share by Application (2018-2029)
Figure 48. World Cancer Immunotherapy Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Cancer Immunotherapy Drug Industry Chain
Figure 50. Cancer Immunotherapy Drug Procurement Model
Figure 51. Cancer Immunotherapy Drug Sales Model
Figure 52. Cancer Immunotherapy Drug Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
